Nexalis Therapeutics Limited (ASX:NX1)
Australia
· Delayed Price · Currency is AUD 0.0210
0.00 (0.00%)
At close: Mar 9, 2026
Nexalis Therapeutics Revenue
In the year 2025, Nexalis Therapeutics had annual revenue of 767.69K AUD with 91.06% growth. Nexalis Therapeutics had revenue of 557.12K in the half year ending June 30, 2025, with 27.13% growth.
Revenue
767.69K
Revenue Growth
+91.06%
P/S Ratio
6.97
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 767.69K | 365.88K | 91.06% |
| Dec 31, 2024 | 401.81K | -802.24K | -66.63% |
| Dec 31, 2023 | 1.20M | 1.18M | 4,755.02% |
| Dec 31, 2022 | 24.80K | -156.94K | -86.35% |
| Dec 31, 2021 | 181.74K | 159.61K | 721.35% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Acrux | 2.81M |
| Zelira Therapeutics | 656.00 |
| Vectus Biosystems | 89.96K |
| Biotron | -868.00 |
| Anatara Lifesciences | 623.76K |
| Invex Therapeutics | 229.08K |
| Chimeric Therapeutics | 9.75M |
| Tissue Repair | 3.38M |